Braxia Scientific Corp. (CSE: BRAXF (OTC: BRAXF (FWB: 4996), a medical research firm with clinics that provide innovative ketamine treatments to people with depression and other disorders, recently provided an update on its leading research role in the psychedelics sector. Braxia Scientific’s research team continues to develop innovative treatments for depression. This includes potential ketamine derivatives. Braxia Scientific also continues to conduct multiple psychedelic-based clinical trials. This adds to the Company’s growing proprietary data that will be used to inform future drug development.
Braxia Scientific has collected comprehensive data on more than 5,200 ketamine-related treatments administered at its network clinics. Braxia Scientific’s researchers published 43 manuscripts on ketamine-related topics in peer-reviewed journals. The Canadian Rapid Treatment Centre of Excellence, a Braxia subsidiary, has a growing database that contains key clinical outcomes to support an ongoing clinical trial of psilocybin assisted therapy.
Dr. Roger McIntyre is the CEO of Braxia Scientific. Braxia Scientific is a leader in the development of psychedelic drugs, thanks to its unmatched human capital, established clinical infrastructure, and large proprietary database.
“With our data and expertise, we can enhance our intellectual property. This includes our work in identifying and developing new chemical entities. Patients will have access to new treatment options for their mental disorders.
The Company’s clinical expertise has been a key factor in the expansion of the company’s infrastructure for innovative interventions, including ketamine, and psilocybin, as well as other potential future psychedelics.
The Company continues to be a leader in psychedelics, having established best practices guidelines and treatment protocols, as well as innovative therapies such as psilocybin. The publication by American Journal of Psychiatry of International Expert Opinion and Implementation Guidance by Braxia Scientific, which was written by Braxia Scientific’s leaders, illustrates the Company’s leadership. It outlines Ketamine and Esketamine treatment parameters and sets a standard for clinical implementation of rapid-acting treatment options in people with treatment-resistant depression.
